Profile: Eli Lilly and Co (LLY.F)

LLY.F on Frankfurt Stock Exchange

47.60EUR
10:45am EDT
Price Change (% chg)

€0.76 (+1.63%)
Prev Close
€46.83
Open
€46.91
Day's High
€47.60
Day's Low
€46.91
Volume
460
Avg. Vol
1,494
52-wk High
€47.60
52-wk Low
€35.05

Search Stocks
Eli Lilly and Company, discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 15 other countries. Its products are sold in approximately 130 countries. The Company’s products include neuroscience products, endocrinology products, oncology products, cardiovascular products, animal health products and other pharmaceuticals. The Company’s new molecular entities (NMEs) are in Phase III clinical trial testing include Dulaglutide, Edivoxetine, Empagliflozin-BI10773, Enzastaurin, Ixekizumab, Necitumumab,, New insulin glargine product, Novel basal insulin analog, Pomaglumetad Methionil, Ramucirumab, Solanezumab and Tabalumab. In July 2014, Anthera Pharmaceuticals Inc acquired Sollpura (liprotamase), a investigational Pancreatic Enzyme Replacement Therapy (PERT) from Eli Lilly and Company.

Company Address

Eli Lilly and Co

Lilly Corporate Center
INDIANAPOLIS   IN   46285
P: +1317.2762000
F: +1317.2763492

Search Stocks